Format
Sort by

Send to

Choose Destination

Search results

Items: 18

1.

The effect of levodopa-carbidopa intestinal gel infusion long-term therapy on motor complications in advanced Parkinson's disease: a multicenter Romanian experience.

Băjenaru O, Ene A, Popescu BO, Szász JA, Sabău M, Mureşan DF, Perju-Dumbrava L, Popescu CD, Constantinescu A, Buraga I, Simu M.

J Neural Transm (Vienna). 2016 Apr;123(4):407-14. doi: 10.1007/s00702-015-1496-z. Epub 2015 Dec 23.

2.

Progressive Dopamine Transporter Binding Loss in Autopsy-Confirmed Corticobasal Degeneration.

Pirker S, Perju-Dumbrava L, Kovacs GG, Traub-Weidinger T, Pirker W.

J Parkinsons Dis. 2015;5(4):907-12. doi: 10.3233/JPD-150625.

PMID:
26485425
3.

Efficacy and safety of lacosamide as first add-on or later adjunctive treatment for uncontrolled partial-onset seizures: A multicentre open-label trial.

Zadeh WW, Escartin A, Byrnes W, Tennigkeit F, Borghs S, Li T, Dedeken P, De Backer M; SP0954 Study Group.

Seizure. 2015 Sep;31:72-9. doi: 10.1016/j.seizure.2015.07.001. Epub 2015 Jul 10.

4.

Correlation of striatal dopamine transporter imaging with post mortem substantia nigra cell counts.

Kraemmer J, Kovacs GG, Perju-Dumbrava L, Pirker S, Traub-Weidinger T, Pirker W.

Mov Disord. 2014 Dec;29(14):1767-73. doi: 10.1002/mds.25975. Epub 2014 Jul 22.

PMID:
25048738
5.

Intracellular processing of disease-associated α-synuclein in the human brain suggests prion-like cell-to-cell spread.

Kovacs GG, Breydo L, Green R, Kis V, Puska G, Lőrincz P, Perju-Dumbrava L, Giera R, Pirker W, Lutz M, Lachmann I, Budka H, Uversky VN, Molnár K, László L.

Neurobiol Dis. 2014 Sep;69:76-92. doi: 10.1016/j.nbd.2014.05.020. Epub 2014 May 27.

PMID:
24878508
6.

Circadian Variation of Stroke Onset: A Hospital-Based Study.

Fodor DM, Babiciu I, Perju-Dumbrava L.

Clujul Med. 2014;87(4):242-9. doi: 10.15386/cjmed-328. Epub 2014 Nov 12.

7.

Randomized trial of IPX066, carbidopa/levodopa extended release, in early Parkinson's disease.

Pahwa R, Lyons KE, Hauser RA, Fahn S, Jankovic J, Pourcher E, Hsu A, O'Connell M, Kell S, Gupta S; APEX-PD Investigators.

Parkinsonism Relat Disord. 2014 Feb;20(2):142-8. doi: 10.1016/j.parkreldis.2013.08.017. Epub 2013 Sep 5.

8.

Cerebrovascular profile assessment in Parkinson's disease patients.

Perju-Dumbravă L, Muntean ML, Muresanu DF.

CNS Neurol Disord Drug Targets. 2014;13(4):712-7.

PMID:
24040791
9.

Delayed postirradiation camptocormia.

Kelly L, Perju-Dumbrava LD, Thyagarajan D, Lee YC.

BMJ Case Rep. 2013 Aug 19;2013. pii: bcr2013200083. doi: 10.1136/bcr-2013-200083.

10.

Dopamine D2 receptor SPECT in corticobasal syndrome and autopsy-confirmed corticobasal degeneration.

Pirker S, Perju-Dumbrava L, Kovacs GG, Traub-Weidinger T, Asenbaum S, Pirker W.

Parkinsonism Relat Disord. 2013 Feb;19(2):222-6. doi: 10.1016/j.parkreldis.2012.10.010. Epub 2012 Oct 31.

PMID:
23121727
11.

Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis.

Radue EW, O'Connor P, Polman CH, Hohlfeld R, Calabresi P, Selmaj K, Mueller-Lenke N, Agoropoulou C, Holdbrook F, de Vera A, Zhang-Auberson L, Francis G, Burtin P, Kappos L; FTY720 Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) Study Group.

Arch Neurol. 2012 Oct;69(10):1259-69.

PMID:
22751847
12.

Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study.

Devonshire V, Havrdova E, Radue EW, O'Connor P, Zhang-Auberson L, Agoropoulou C, Häring DA, Francis G, Kappos L; FREEDOMS study group.

Lancet Neurol. 2012 May;11(5):420-8. doi: 10.1016/S1474-4422(12)70056-X. Epub 2012 Apr 10. Erratum in: Lancet Neurol. 2012 Aug;11(8):658.

PMID:
22494956
13.

Sustained response to deep brain stimulation in LRRK2 parkinsonism with the Y1699C mutation.

Perju-Dumbrava LD, McDonald M, Kneebone AC, Long R, Thyagarajan D.

J Parkinsons Dis. 2012;2(4):269-71. doi: 10.3233/JPD-012121.

PMID:
23938256
14.

Dopamine transporter imaging in autopsy-confirmed Parkinson's disease and multiple system atrophy.

Perju-Dumbrava LD, Kovacs GG, Pirker S, Jellinger K, Hoffmann M, Asenbaum S, Pirker W.

Mov Disord. 2012 Jan;27(1):65-71. doi: 10.1002/mds.24000. Epub 2011 Nov 18.

PMID:
22102521
15.

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.

Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, Burtin P; FREEDOMS Study Group.

N Engl J Med. 2010 Feb 4;362(5):387-401. doi: 10.1056/NEJMoa0909494. Epub 2010 Jan 20.

16.
17.
18.

Anticardiolipin-antibodies in stroke and in other neurological disorders.

Perju-Dumbrava L, Zeiler K, Kapiotis S, Deecke L.

Rom J Neurol Psychiatry. 1995 Apr-Jun;33(2):137-43.

PMID:
7547377
Items per page

Supplemental Content

Loading ...
Write to the Help Desk